Intellia Therapeutics (NTLA) Change in Receivables (2016 - 2026)
Intellia Therapeutics (NTLA) reported Change in Receivables of -$337000.0 for Q1 2026, down 116.96% year-over-year from $2.0 million in Q1 2025, and up 78.7% quarter-over-quarter from -$1.6 million in Q4 2025.
Intellia Therapeutics (NTLA) Change in Receivables (2016 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has 11 years of Change in Receivables data on file, last reported at -$337000.0 in Q1 2026.
- Change in Receivables for Q1 2026 came in at -$337000.0, down 116.96% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.4 million (up 94.7% YoY), and the FY2025 annual result was $951000.0, up 103.4% from the prior year.
- Change in Receivables rose to -$337000.0 in Q1 2026 per NTLA's latest filing, from -$1.6 million in the prior quarter.
- Over five years, Change in Receivables peaked at $30.0 million in Q4 2023 and troughed at -$24.1 million in Q2 2024.
- A 5-year average of $417647.1 and a median of -$29000.0 in 2024 frame the typical range for Change in Receivables.
- The sharpest annual moves came in 2023 and 2024: Change in Receivables jumped 11850.98% in 2023, then tumbled 16059.6% in 2024.
- A 5-year view of Change in Receivables shows it stood at -$255000.0 in 2022, then jumped by 11850.98% to $30.0 million in 2023, then tumbled by 101.12% to -$337000.0 in 2024, then sank by 369.44% to -$1.6 million in 2025, then surged by 78.7% to -$337000.0 in 2026.
- Business Quant data shows NTLA's Change in Receivables at -$337000.0 in Q1 2026, -$1.6 million in Q4 2025, and -$303000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -4.08 Mn |
| 10 | Intellia Therapeutics | 1.86 Bn | 1.86 Bn | - | -337,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -337,000.00 |
| Mar 31, 2026 | -337,000.00 |
| Dec 31, 2025 | -1.58 Mn |
| Dec 31, 2025 | -1.58 Mn |
| Sep 30, 2025 | -303,000.00 |
| Sep 30, 2025 | -303,000.00 |
| Jun 30, 2025 | 849,000.00 |
| Jun 30, 2025 | 849,000.00 |
| Mar 31, 2025 | 1.99 Mn |
| Mar 31, 2025 | 1.99 Mn |
| Dec 31, 2024 | -337,000.00 |
| Dec 31, 2024 | -337,000.00 |
| Sep 30, 2024 | -3.47 Mn |
| Sep 30, 2024 | -3.47 Mn |
| Jun 30, 2024 | -24.10 Mn |
| Jun 30, 2024 | -24.10 Mn |
| Mar 31, 2024 | -29,000.00 |
| Mar 31, 2024 | -29,000.00 |
| Dec 31, 2023 | 29.97 Mn |
| Dec 31, 2023 | 29.97 Mn |